1,562
Views
1
CrossRef citations to date
0
Altmetric
Assessment Procedure

Development and validation of the patient-reported “Facial Function Scale” for facioscapulohumeral muscular dystrophy

, , , , , , , , , & show all
Pages 1530-1535 | Received 10 Sep 2021, Accepted 11 Apr 2022, Published online: 16 May 2022
 

Abstract

Purpose

Facial weakness and its functional consequences are an often underappreciated clinical feature of facioscapulohumeral muscular dystrophy (FSHD) by healthcare professionals and researchers. This is at least in part due to the fact that there are few adequate clinical outcome measures available.

Methods

We developed the Facial Function Scale, a Rasch-built questionnaire on the functional disabilities relating to facial weakness in FSHD. A preliminary 33-item questionnaire was created based on semi-structured interviews with 16 FSHD patients and completed by 119 patients. For reliability studies, 73 patients completed it again after a two-week interval. Data were subjected to semi-automated Rasch analysis to select the most appropriate item set to fit model expectations.

Results

This resulted in a 25-item unidimensional, linear-weighted questionnaire with high internal consistency (person separation index = 0.92) and test–retest reliability (patients’ locations ICC = 0.98 and items’ locations ICC = 0.99). Good external construct validity scores were obtained through correlation with the Communicative Participation Item Bank questionnaire, examiner-reported Facial Weakness Score and facial weakness subscale of the FSHD evaluation score (respectively r = 0.733, r = −0.566, and r = 0.441, all p < 0.001).

Conclusions

This study provides a linear-weighted, clinimetrically sound, patient-reported outcome measure on the functional disabilities relating to facial weakness in FSHD, to enable further research on this relevant topic.

    Implications for rehabilitation

  • Facial weakness and its functional consequences are an often underappreciated clinical feature of facioscapulohumeral muscular dystrophy (FSHD), both in symptomatic treatment and in research.

  • To enable the development and testing of therapeutic symptomatic interventions for facial weakness, clinical outcome measures are required.

  • This study provides a linear-weighted, clinimetrically sound, patient-reported outcome measure on the functional disabilities relating to facial weakness in FSHD patients.

Acknowledgements

Several authors of this publication are members of the Radboudumc Center of Expertise for neuromuscular disorders (Radboud-NMD), Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases (EURO-NMD).

Disclosure statement

The authors report no conflicts of interest relevant to the current research.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

This project was funded by the Prinses Beatrix Spierfonds, Grant Number W.OR18-07, and the FSHD Stichting, Grant Number WP29.